Chiron Concludes Phase III Program for Menjugate Meningococcal C Vaccine in United States
EMERYVILLE, Calif. -- Chiron Corporation announced that it has successfully concluded its Phase III trial for Menjugate® meningococcal C vaccine in the United States and will not be filing a Biologics License Application (BLA) for the vaccine. The now-completed Phase III trial in the United States expanded the safety and immunogenicity database for Menjugate, a conjugated vaccine.
Given the changing landscape for meningococcal vaccines in the United States, we believe that our resources are better deployed by focusing on advancing our quadravalent vaccine candidate for serogroups A, C, W and Y, said John Lambert, president, Chiron Vaccines. We have learned a great deal from the Phase III study of Menjugate, and we will apply that experience to move our ACWY vaccine candidate through development.
Chirons meningococcal ACWY vaccine is currently in Phase II. The company initiated a Phase II study in infants this year and plans to initiate a Phase III program for the vaccine in 2005.
Source: Chiron
A Helping Hand: Innovative Approaches to Expanding Hand Hygiene Programs in Acute Care Settings
July 9th 2025Who knew candy, UV lights, and a college kid in scrubs could double hand hygiene adherence? A Pennsylvania hospital’s creative shake-up of its infection prevention program shows that sometimes it takes more than soap to get hands clean—and keep them that way.
Broadening the Path: Diverse Educational Routes Into Infection Prevention Careers
July 4th 2025Once dominated by nurses, infection prevention now welcomes professionals from public health, lab science, and respiratory therapy—each bringing unique expertise that strengthens patient safety and IPC programs.
How Contaminated Is Your Stretcher? The Hidden Risks on Hospital Wheels
July 3rd 2025Despite routine disinfection, hospital surfaces, such as stretchers, remain reservoirs for harmful microbes, according to several recent studies. From high-touch areas to damaged mattresses and the effectiveness of antimicrobial coatings, researchers continue to uncover persistent risks in environmental hygiene, highlighting the critical need for innovative, continuous disinfection strategies in health care settings.
